Chung, Sutro Biopharma CEO, buys $10k in STRO stock

Jane Chung, Chief Executive Officer of Sutro Biopharma, Inc. (NASDAQ:STRO), acquired 12,500 shares of common stock on October 15, 2025, at a price of $0.8009 per share, in a purchase worth $10,011. The purchase comes as the stock trades near its 52-week low of $0.52, having declined nearly 80% over the past year. According to InvestingPro analysis, the company currently appears undervalued. Following the transaction, Chung directly owns 122,850 shares of Sutro Biopharma , representing a notable stake in the $66 million market cap company. While the company holds more cash than debt on its balance sheet, InvestingPro data reveals 10+ additional key insights about STRO’s financial health and future prospects.

In other recent news, Sutro Biopharma announced an organizational restructuring that will reduce its workforce by approximately one-third. This move is aimed at prioritizing its antibody drug conjugate (ADC) programs and is expected to extend the company’s financial runway into at least mid-2027, aided by anticipated milestone payments. Additionally, Sutro Biopharma plans to announce initial clinical data from its STRO-004 program and initiate clinical studies for at least one more ADC program. The company has also partnered with the U.S. Food and Drug Administration to develop reference materials for ADCs, aiming to improve regulatory standards and analytical methods. In analyst updates, Citizens JMP’s Reni Benjamin has reiterated a Market Perform rating for Sutro Biopharma following its second-quarter 2025 earnings announcement. The company reaffirmed its intention to file an Investigational New Drug application for STRO-004 in the latter half of 2025. These developments reflect Sutro Biopharma’s strategic focus on advancing its ADC programs and enhancing regulatory frameworks.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.